The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major bleeding was significantly higher in aspirin - treated
patients than in the placebo group (4.6 percent vs. 3.7 percent).
Not exact matches
A significantly higher percentage of
patients receiving pinaverium reported that their IBS symptoms improved (60 percent)
than in the
placebo group (34 percent).
In a landmark 1999 study, Harvard psychiatrist Andrew Stoll found that bipolar
patients who were given large doses of omega - 3s did significantly better and resisted relapse longer
than a matched
group of
patients who were given
placebos.
Many of the trials are based on small samples of
patients, less
than 10
in each of the drug and
placebo groups.
By the end of treatment, the odds of experiencing a heavy drinking day
in the
placebo group was five times more
than that of the topiramate
group; and the number of
patients who experienced no heavy drinking days on the last four weeks of treatment
in the topirmate
group was more
than double that of the
placebo group.
In fact, more patients in the placebo arm stopped taking treatment than those who received the fish - oil supplements (17.9 % in n - 3 fatty acid group vs 19.4 % in the placebo group
In fact, more
patients in the placebo arm stopped taking treatment than those who received the fish - oil supplements (17.9 % in n - 3 fatty acid group vs 19.4 % in the placebo group
in the
placebo arm stopped taking treatment
than those who received the fish - oil supplements (17.9 %
in n - 3 fatty acid group vs 19.4 % in the placebo group
in n - 3 fatty acid
group vs 19.4 %
in the placebo group
in the
placebo group).
For example, people who were taking only an inactive
placebo were more likely
than patients in other
groups to drop out of study, suggesting these families had noticed the
placebo «medication» wasn't working.